DrugPatentWatch Database Preview
Drugs in Development Information for Tegafur
Drug Development Status for Tegafur: Patents, clinical trial progress, indications
Tegafur is an investigational drug.
There have been 119 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Taiwan University Hospital.
There are two US patents protecting this investigational drug and twenty-seven international patents.
Summary for Tegafur
| US Patents | 2,424 |
| International Patents | 27,522 |
| US Patent Applications | 5,847 |
| WIPO Patent Applications | 1,082 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 3 (2014-09-01) |
| Vendors | 63 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| SOX-based CRT for Esophageal Cancer. | Zhejiang Provincial People’s Hospital | Phase 1/Phase 2 |
| S-1 for 9 Months Versus 1 Year for Gastric Cancer Staged II（SMAC） | Fudan University | Phase 2 |
| Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | Zhejiang Cancer Hospital | Phase 2 |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegafur | Start Trial | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | Start Trial |
| Tegafur | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Tegafur | Start Trial | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Protalix Ltd. (Carmiel, IL) | Start Trial |
| Tegafur | Start Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| Tegafur | Start Trial | Nuclear targeting sequences | Yeda Research and Development Co. Ltd. (Rehovot, IL) | Start Trial |
| Tegafur | Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegafur
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegafur | Australia | 2014232383 | 2033-03-15 | Start Trial |
| Tegafur | Australia | 2019202731 | 2033-03-15 | Start Trial |
| Tegafur | Brazil | 112015023267 | 2033-03-15 | Start Trial |
| Tegafur | Canada | 2906931 | 2033-03-15 | Start Trial |
| Tegafur | China | 105142635 | 2033-03-15 | Start Trial |
| Tegafur | Eurasian Patent Organization | 201591607 | 2033-03-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
